A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma

Frank Stenner, Rahel Chastonay, Heike Liewen, Sarah R. Haile, Richard Cathomas, Christian Rothermundt, Raffaele D. Siciliano, Susanna Stoll, Alexander Knuth, Tomas Buchler, Camillo Porta, Christoph Renner, Panagiotis Samaras

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. Results: In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95% CI for difference 1.45-5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95% CI for difference -1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95% CI 1.02-4.3, p = 0.003). Conclusion: The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.

Original languageEnglish
Pages (from-to)333-340
Number of pages8
JournalOncology
Volume82
Issue number6
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Receptor Protein-Tyrosine Kinases
Therapeutics
Linear Models
sorafenib
sunitinib
Pharmaceutical Preparations

Keywords

  • Renal cell carcinoma
  • Sorafenib
  • Sunitinib
  • Treatment regimens
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Stenner, F., Chastonay, R., Liewen, H., Haile, S. R., Cathomas, R., Rothermundt, C., ... Samaras, P. (2012). A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology, 82(6), 333-340. https://doi.org/10.1159/000338001

A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. / Stenner, Frank; Chastonay, Rahel; Liewen, Heike; Haile, Sarah R.; Cathomas, Richard; Rothermundt, Christian; Siciliano, Raffaele D.; Stoll, Susanna; Knuth, Alexander; Buchler, Tomas; Porta, Camillo; Renner, Christoph; Samaras, Panagiotis.

In: Oncology, Vol. 82, No. 6, 07.2012, p. 333-340.

Research output: Contribution to journalArticle

Stenner, F, Chastonay, R, Liewen, H, Haile, SR, Cathomas, R, Rothermundt, C, Siciliano, RD, Stoll, S, Knuth, A, Buchler, T, Porta, C, Renner, C & Samaras, P 2012, 'A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma', Oncology, vol. 82, no. 6, pp. 333-340. https://doi.org/10.1159/000338001
Stenner F, Chastonay R, Liewen H, Haile SR, Cathomas R, Rothermundt C et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology. 2012 Jul;82(6):333-340. https://doi.org/10.1159/000338001
Stenner, Frank ; Chastonay, Rahel ; Liewen, Heike ; Haile, Sarah R. ; Cathomas, Richard ; Rothermundt, Christian ; Siciliano, Raffaele D. ; Stoll, Susanna ; Knuth, Alexander ; Buchler, Tomas ; Porta, Camillo ; Renner, Christoph ; Samaras, Panagiotis. / A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. In: Oncology. 2012 ; Vol. 82, No. 6. pp. 333-340.
@article{ef813999a3d64009a0873f513853670c,
title = "A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma",
abstract = "Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. Results: In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95{\%} CI for difference 1.45-5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95{\%} CI for difference -1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95{\%} CI 1.02-4.3, p = 0.003). Conclusion: The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.",
keywords = "Renal cell carcinoma, Sorafenib, Sunitinib, Treatment regimens, Tyrosine kinase inhibitors",
author = "Frank Stenner and Rahel Chastonay and Heike Liewen and Haile, {Sarah R.} and Richard Cathomas and Christian Rothermundt and Siciliano, {Raffaele D.} and Susanna Stoll and Alexander Knuth and Tomas Buchler and Camillo Porta and Christoph Renner and Panagiotis Samaras",
year = "2012",
month = "7",
doi = "10.1159/000338001",
language = "English",
volume = "82",
pages = "333--340",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "6",

}

TY - JOUR

T1 - A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma

AU - Stenner, Frank

AU - Chastonay, Rahel

AU - Liewen, Heike

AU - Haile, Sarah R.

AU - Cathomas, Richard

AU - Rothermundt, Christian

AU - Siciliano, Raffaele D.

AU - Stoll, Susanna

AU - Knuth, Alexander

AU - Buchler, Tomas

AU - Porta, Camillo

AU - Renner, Christoph

AU - Samaras, Panagiotis

PY - 2012/7

Y1 - 2012/7

N2 - Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. Results: In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95% CI for difference 1.45-5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95% CI for difference -1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95% CI 1.02-4.3, p = 0.003). Conclusion: The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.

AB - Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results into a pooled analysis of available data from other publications. Differences in median progression-free survival (PFS) for first- (PFS1) and second-line treatment (PFS2), and for the combined PFS (PFS1 plus PFS2) were examined using weighted linear regression. Results: In the pooled analysis encompassing 853 patients, the median combined PFS for first-line sunitinib and 2nd-line sorafenib (SuSo) was 12.1 months compared with 15.4 months for the reverse sequence (SoSu; 95% CI for difference 1.45-5.12, p = 0.0013). Regarding first-line treatment, no significant difference in PFS1 was noted regardless of which drug was initially used (0.62 months average increase on sorafenib, 95% CI for difference -1.01 to 2.26, p = 0.43). In second-line treatment, sunitinib showed a significantly longer PFS2 than sorafenib (average increase 2.66 months, 95% CI 1.02-4.3, p = 0.003). Conclusion: The SoSu sequence translates into a longer combined PFS compared to the SuSo sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.

KW - Renal cell carcinoma

KW - Sorafenib

KW - Sunitinib

KW - Treatment regimens

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84861880926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861880926&partnerID=8YFLogxK

U2 - 10.1159/000338001

DO - 10.1159/000338001

M3 - Article

C2 - 22677881

AN - SCOPUS:84861880926

VL - 82

SP - 333

EP - 340

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 6

ER -